Skip to main content

Table 1 Baseline renal status in EMPA-REG OUTCOME, CANVAS program, DECLARE-TIMI 58, VERTIS CV, CREDENCE, and DAPA-CKD

From: Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk

Baseline mean eGFR (mL/min/1.73 m2)

EMPA-REG OUTCOME

CANVAS program

DECLARE-TIMI 58

VERTIS CV

CREDENCE

DAPA-CKDb

74

77

85

76

56

44

eGFR

N (%)

Mean (SD)a

N (%)

Mean (SD)

N (%)

Mean (SD)

N (%)

Mean (SD)

N (%)

Mean (SD)

N (%)

Mean (SD)

 ≥ 90 mL/min/1.73 m2

1538 (21.9)

82.9 (NR)

2476 (24.4)

103.2 (13.2)

8162 (47.6)

98.3 (6.5)

2048 (24.8)

NR

211 (4.8)

NR

348 (12.0)

NR

 ≥ 60 to < 90 mL/min/1.73 m2

3661 (52.2)

48.5 (NR)

5625 (55.5)

74.6 (8.3)

7732 (45.0)

77.0 (8.5)

4390 (53.2)

 

1558 (35.4)

 

918 (31.6)

 

 ≥ 45 to < 60 mL/min/1.73 m2

1249 (17.8)

1485 (14.6)

53.2 (4.2)

1265 (7.4)

51.4 (7.2)

1807 (21.9)

 

1266 (28.8)

 

1239 (42.6)

 

 ≥ 30 to < 45 mL/min/1.73 m2

570 (8.1)

554 (5.5)

38.2 (5.1)

–

–

–

 

1191 (27.1)

 

401 (13.8)

 

 ≥ 15 to < 30 mL/min/1.73 m2

–

–

–

–

–

–

 

172 (3.9)

   

 < 15 mL/min/1.73 m2

–

–

–

–

–

 –

 

2 (< 0.1)

   

Baseline median UACR (mg/g)

18

12

13

NR

927

1017

UACR, N (%)

 Normoalbuminuria (< 30 mg/g)

4171 (60.0)

7007 (69.8)

11,652 (67.9)

NR

31 (0.7)

1 (0.0)

 Microalbuminuria (30 to ≤ 300 mg/g)

2013 (29.0)

2266 (22.6)

4023 (23.4)

 

496 (11.3)

308 (10.6)

 Macroalbuminuria (> 300 to ≤ 3000 mg/g)

769 (11.1)

760 (7.6)

1169 (6.8)

 

3371 (76.6)

2597 (89.4)

 Nephrotic range (> 3000 mg/g)

–

–

–

 

503 (11.4)

1 (0.0)

  1. eGFR estimated glomerular filtration rate, NR not reported, SD standard deviation, UACR urine albumin:creatinine ratio [22, 32, 35,36,37,38]
  2. aFor EMPA-REG OUTCOME, mean (SD) eGFRs were only available for patients ≥ 60 mL/min/1.73 m2 and < 60 mL/min/1.73 m2
  3. bFor DAPA-CKD, only data from the T2D sub-population is presented